Partner Content Partner Content Intellectual Property and Regulatory Law: Recent Development... Parallel Trade 2018
News Sandoz weighs into European rituximab biosimilar market Sandoz has gained European approval for its biosimilar version of Roche's blockbuster MabThera/Rituxan (rituximab) to be called Rixathon.
Views & Analysis Putting patients as partners The impact of European Patients’ Forum’s campaign for patient empowerment.
Views & Analysis Are European incentives speeding access in rare cancer treat... Examining the impact of support programmes for orphan treatments.
News Janssen's quarterly schizophrenia drug approved in EU Company hopes new formulation will improve patient outcomes.
Articles Brexit would be a blow for UK life sciences – regulators and... The British public is still split over Brexit – but pharma is warning of potentially serious consequences if the country votes 'Leave' on 23 June. Andrew McConaghie reports.
News Neuralink gets okay for its first international trial Elon Musk's brain-computer interface (BCI) company Neuralink has been given the green light to test its device in tetraplegic patients in Canada
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
